OSAKA SODA CO., LTD.

CONSOLIDATED FINANCIAL RESULTS For the quarterly period ended June 30, 2017 (Prepared under Japan GAAP, unaudited)

Company name: OSAKA SODA CO., LTD. Stock Exchange Listing: Tokyo Securities code: 4046 URL: http://www.osaka-soda.co.jp

Representative: Kenshi Terada, Representative Director, Chief Operating Officer

For inquiry: Takuya Kajino, General Manager, Administration Division

(Telephone: +81-6-6110-1560)

Scheduled date of filing of quarterly securities report: Aug 7, 2017

Scheduled date of commencement of dividend payment: -

Supplementary materials prepared for the financial results: None Quarterly financial results briefings: None

1. Consolidated Financial Results (1)Results of Operations

(Amounts are rounded down to the nearest million yen)

		Three Months Ended			
		June 30, 2017 June 30, 2016			0, 2016
		Change *			Change *
Net sales	Millions of yen	23,634	4.2%	22,686	(8.7)%
Operating income	Millions of yen	1,528	(4.9)%	1,606	25.4%
Ordinary income	Millions of yen	1,814	92.0%	945	(40.8)%
Net income	Millions of yen	1,226	139.0%	513	(49.6)%
Comprehensive income	Millions of yen	2,144	- %	(193)	- %
Net income per share	Yen	11.64	-	4.87	-
Diluted net income per share	Yen	9.65	-	4.04	_

Note: Percent changes for three months are year-on-year comparisons.

(2)Financial Condition

		June 30, 2017	March 31, 2017
Total assets	Millions of yen	102,512	101,503
Net assets	Millions of yen	54,238	52,725
Equity *	Millions of yen	54,238	52,725
Equity ratio	%	52.9	51.9

Note: Equity="Total net assets" minus "Subscription rights to shares"

2. Dividends

	Year ending Mar. 31, 2018 (Forecast)	Year ending Mar. 31, 2018	Year ended Mar. 31, 2017
End of first quarter		_	_
End of second quarter	5.50		5.00
End of third quarter	_		_
End of fourth quarter	27.50		6.00
Full year	_		11.00

* The share consolidation proposed by OSAKA SODA CO., LTD. (the "Company") was approved by shareholders at the 162nd Ordinary Meeting of Shareholders held on June 29, 2017. The Company's consolidation of its common shares will be completed effective October 1st, 2017 on the basis of one (1) new post-consolidation common share for every five (5) pre-consolidation common shares (the "Ratio"). As a result, the forecast of dividend per share for the year ending March 31, 2018 will be ¥27.50 per share on a post-consolidation basis from ¥5.50 per share on a pre-consolidation basis. Calculating annual dividend for the same fiscal year ending March 31, 2018 is not possible in accordance with the Ratio. The annual dividend for the same fiscal ending will be ¥11.0 per share on a pre-consolidation basis.

3. Earnings Forecast for the fiscal year ending March 31, 2018

		First half		Full-ye	ear
			Change*		Change*
Net sales	Millions of yen	47,000	2.4%	100,000	6.9%
Operating income	Millions of yen	3,300	1.6%	7,000	6.3%
Ordinary income	Millions of yen	3,300	26.9%	7,000	7.1%
Net income	Millions of yen	2,200	24.7%	4,600	6.5%
Earnings per share	Yen	20.88	-	218.32	-

Note: Percent changes for three months are year-on-year comparisons.

* The share consolidation proposed by OSAKA SODA CO., LTD. (the "Company") was approved by shareholders at the 162nd Ordinary Meeting of Shareholders held on June 29, 2017. The Company's consolidation of its common shares will be completed effective October 1st, 2017 on the basis of one (1) new post-consolidation common share for every five (5) pre-consolidation common shares. As a result, the forecast of earnings per share for the fiscal year ending March 31, 2018 will be ¥218.32 per share on a postconsolidation basis from ¥43.37 per share on a pre-consolidation basis.

* Notes

(1) Changes in significant subsidiaries during the current quarterly period (Changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Application of accounting methods used specifically for the preparation of quarterly consolidated financial statements:

None

(3) Changes in accounting policies, accounting estimates and restatements of revisions

None None

1) Changes in accounting policies due to revisions of accounting standards, etc.:

None

2) Changes in accounting policies other than 1):

None

3) Changes in accounting estimates:

4) Restatement of revisions:

None

(4) Number of outstanding shares (common stock)

1	Number of shares	outstanding a	at the end of the i	period (including treasury	/ shares)

As of June 30, 2017:	111,778,205	shares
As of March 31, 2017:	111,773,837	shares
2) Number of treasury shares at the end of period		
As of June 30, 2017:	6,430,577	shares
As of March 31, 2017:	6,428,225	shares
3) Average number of shares outstanding in each period		
Three months ended June 30, 2017	105,345,910	shares

105,351,694 shares

This quarterly financial results are not subject to the quarterly review procedure in accordance with the Financial Instruments and Exchange Act. The quarterly review procedure of consolidated financial statements has not been completed at the time of disclosure.

*Appropriate use of financial forecasts, other special notes

Three months ended June 30, 2016

This material contains forward-looking statements such as earnings forecast about OSAKA SODA CO., LTD. and its group companies ("Osaka Soda Group"). These forward-looking statements are based on the current assumptions and beliefs of Osaka Soda Group in light of the information currently available to it, and contain known and unknown risks, uncertainties and other factors. Osaka Soda Group therefore wishes to caution readers that actual results could be materially different from any future results.

DISCLAIMER:

This is an English translation of the original Japanese document and is prepared for reference. Should there be any inconsistency between the translation and the Japanese original, the latter shall prevail.

^{*} Status of quarterly review procedure:

4. Qualitative Information

(1)Results of Operations

During the three months ended June 30, 2017, Japan's economy has continued its moderate recovery trend, with improvements in the employment situation and corporate profits, though the outlook remains dim on slowing down of emerging economies including China and the extent of political and economic uncertainty.

Under the circumstances, Osaka Soda Group has taken the following things.

Basic Chemical Products

Manufacturing systems have been developed with a focus on efficiency to enhance cost competitiveness and sales price adjustments have been implemented in response to the fluctuations of raw material and fuel price.

Functional Chemical Products

Increasing overseas sales activity has been performed to expand global sales of our main products such as *Epichlorohydrin*, *Diallyl Phthalate Resin*, and *Allyl Ethers*. The early stages of new product and business launches, such as Acrylic Rubber that entered into market in April, have taken place. With regard to Healthcare-related businesses, it is positioned as a third pillar of profit. In *Active Pharmaceutical Ingredients and their Intermediates*, the purchase order of contract manufacturing, especially in specialty instruments, has been achieved good progress. In *Separation Media in Pharmaceutical Industry (Silica Gel for Liquid Chromatography)*, the development of new customer has been implemented in India as well as East Europe and China.

Housing Facilities and Others

A process of setting and managing business portfolio priorities has been implemented for strengthening the profitability.

The following is a summary of reporting segments.

Basic Chemical Products

In Chlor-Alkali, the unit price of sales increased due to sales price adjustments of Caustic Soda.

In *Epichlorhydrin*, net sales increased due to continued steady domestic sales as well as export sales.

As a result, net sales in Basic Chemical Products were ¥10,018 million, an increase of 1.8% compared to the same period of fiscal 2016.

Functional Chemical Products

In **Separation Media in Pharmaceutical Industry** (Silica Gel for Liquid Chromatography), net sales decreased due to inventory adjustments by major European customers, despite sales growth for bio drugs purification in China as well as continued steady sales applied for analysis and Active Pharmaceutical Ingredients in domestic market.

In *Active Pharmaceutical Ingredients and their Intermediates*, net sales increased due to continued steady sales in new Antiviral Drugs, Drugs to treat insomnia, and materials for Medicated Cosmetics.

In *Diallyl Phthalate Resin*, net sales increased due to continued steady export sales to Europe in energy saving UV Inks.

In Allyl Ethers, net sales increased due mainly to sales growth for silane coupling agent.

In *Epichlorhydrin Rubber*, net sales increased due to continued steady sales to Europe in addition to domestic recovery. The sale of acrylic rubber started in earnest as well.

As a result, net sales in Functional Chemical Products were ¥9,683 million, an increase of 10.9% compared to the same period of fiscal 2016.

Housing Facilities and Others

Net sales were ¥3,932 million, a decrease of 4.4% compared to the same period of fiscal 2016.

As a result, net sales were ¥23,634 million, an increase of 4.2% compared to the same period of fiscal 2016. Operating income was ¥1,528 million, a decrease of 4.9% compared to the same period of fiscal 2016. Ordinary income was ¥1,814 million, an increase of 92.0% compared to the same period of fiscal 2016. Net income attributable to owners of parent was ¥1,226 million, an increase of 139.0% compared to the same period of fiscal 2016.

(2) Financial Condition

Assets

Current assets were ¥58,030 million, a decrease of 1.2% since March 31, 2017. The decrease was due primarily to a decrease of ¥288 million in *cash and deposits*.

Noncurrent assets were ¥44,481 million, an increase of 4.0% since March 31, 2017. The increase was due primarily to an increase of ¥1,313 million in *investment securities*.

As a result, Total assets were ¥102,512 million, an increase of 1.0% since March 31, 2017.

Liabilities

Current liabilities were ¥30,970 million, a decrease of 1.3% since March 31, 2017. The decrease was due primarily to a decrease of ¥ ¥965 million in *income taxes payable*.

Noncurrent liabilities were ¥17,303 million, a decrease of 0.5% since March 31, 2017. The decrease was due primarily to a decrease of ¥400 million in *long term loans payable*.

As a result, *Total liabilities* were ¥48,273 million, a decrease of 1.0% since March 31, 2017.

Net assets

Net assets were ¥54,238 million, an increase of 2.9% since March 31, 2017.

(3) Earnings Forecasts

There are no revisions to the earnings forecast from the previous forecast announced in the "Consolidated financial results for the year ended March 31, 2016" dated on May 9, 2017.

5. Consolidated Financial Statements

CONSOLIDATED BALANCE SHEETS

	March 31, 2017	June 30, 2017
Assets		
Current assets		
Cash and deposits	11,033	10,745
Notes and accounts receivable-trade	25,397	24,234
Electronically recorded monetary claims	2,497	3,756
Short term investment securities	9,499	9,499
Merchandise and finished goods	5,743	5,530
Work in process	1,411	1,604
Raw materials and supplies	1,667	1,721
Other current assets	1,491	940
Less: Allowance for doubtful accounts	(3)	(3)
Total current assets	58,739	58,030
Noncurrent assets		
Property, plant, and equipment		
Property, plant, and equipment - Net	11,339	10,940
Other - Net	10,216	11,005
Total property, plant and equipment	21,555	21,945
Intangible assets		
Goodwill	769	752
Other	437	500
Total intangible assets	1,207	1,252
Investments and other assets		·
Investment securities	18,927	20,240
Other, net	1,641	1,608
Less: Allowance for doubtful accounts	(568)	(566)
Total investment and other assets	20,001	21,283
Total noncurrent assets	42,764	44,481
Total assets	101,503	102,512

CONSOLIDATED BALANCE SHEETS (Continued)

Liabilities Current liabilities Notes and accounts payable trade 13,339 13,815 Short term loans payable 8,880 8,880 Current portion of long term loans payable 2,160 1,960 Income taxes payable 1,311 346 Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total sesets 48,778 48,273 Net assets Shareholders' equity 2 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,6		March 31, 2017	June 30, 2017
Notes and accounts payable - trade 13,339 13,815 Short term loans payable 8,880 8,880 Current portion of long term loans payable 2,160 1,960 Income taxes payable 1,311 346 Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 800 400 Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 248,273 Net assets Shareholders' equity 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (Liabilities		
Short term loans payable 8,880 8,880 Current portion of long term loans payable 2,160 1,960 Income taxes payable 1,311 346 Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total inductrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehe	Current liabilities		
Current portion of long term loans payable 2,160 1,960 Income taxes payable 1,311 346 Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 31,390 30,970 Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 5,268 Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171	Notes and accounts payable- trade	13,339	13,815
Income taxes payable 1,311 346 Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 31,390 30,970 Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income 6,481 7,388 Deferred gain	Short term loans payable	8,880	8,880
Provision for bonuses 712 382 Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 31,390 30,970 Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 10,882 10,883 Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive incom	Current portion of long term loans payable	2,160	1,960
Other current liabilities 4,987 5,586 Total current liabilities 31,390 30,970 Noncurrent liabilities 31,390 30,970 Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 9,399 9,400 Retained earnings 27,694 28,558 27,694 28,558 Treasury stock (1,670) (1,671) 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments <td>Income taxes payable</td> <td>1,311</td> <td>346</td>	Income taxes payable	1,311	346
Total current liabilities 31,390 30,970 Noncurrent liabilities 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 20,883 10,882 10,883 Capital stock 10,882 10,883 <td>Provision for bonuses</td> <td>712</td> <td>382</td>	Provision for bonuses	712	382
Noncurrent liabilities Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 48,778 48,273 Net assets Shareholders' equity 10,882 10,883 Capital stock 10,882 10,883 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements	Other current liabilities	4,987	5,586
Bonds with subscription rights to shares 9,999 9,997 Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity 20,200 10,882 10,883 Capital stock 10,882 10,883	Total current liabilities	31,390	30,970
Long term loans payable 800 400 Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total net assets 52,725 54,238	Noncurrent liabilities	_	
Provision for directors retirement benefits 567 557 Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total net assets 52,725 54,238	Bonds with subscription rights to shares	9,999	9,997
Net defined benefit liability 2,927 2,911 Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Long term loans payable	800	400
Other noncurrent liabilities 3,093 3,437 Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income 0,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Provision for directors retirement benefits	567	557
Total noncurrent liabilities 17,387 17,303 Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Net defined benefit liability	2,927	2,911
Total liabilities 48,778 48,273 Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Other noncurrent liabilities	3,093	3,437
Net assets Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Total noncurrent liabilities	17,387	17,303
Shareholders' equity Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Total liabilities	48,778	48,273
Capital stock 10,882 10,883 Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Net assets	_	
Capital surplus 9,399 9,400 Retained earnings 27,694 28,558 Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Shareholders' equity		
Retained earnings27,69428,558Treasury stock(1,670)(1,671)Total shareholders' equity46,57647,171Accumulated other comprehensive incomeValuation difference on available-for-sale securities6,4817,388Deferred gains or losses on hedges(13)(6)Foreign currency translation adjustments2416Re-measurements of defined benefit plans(342)(331)Total accumulated other comprehensive income6,1497,067Total net assets52,72554,238	Capital stock	10,882	10,883
Treasury stock (1,670) (1,671) Total shareholders' equity 46,576 47,171 Accumulated other comprehensive income Valuation difference on available-for-sale securities 6,481 7,388 Deferred gains or losses on hedges (13) (6) Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Capital surplus	9,399	9,400
Total shareholders' equity Accumulated other comprehensive income Valuation difference on available-for-sale securities Deferred gains or losses on hedges Foreign currency translation adjustments Re-measurements of defined benefit plans Total accumulated other comprehensive income Total net assets 47,171 46,576 47,171 46,576 47,171 (6) 7,388 (13) (6) (13) (6) (342) (331) 7,067 7,067	Retained earnings	27,694	28,558
Accumulated other comprehensive incomeValuation difference on available-for-sale securities6,4817,388Deferred gains or losses on hedges(13)(6)Foreign currency translation adjustments2416Re-measurements of defined benefit plans(342)(331)Total accumulated other comprehensive income6,1497,067Total net assets52,72554,238	Treasury stock	(1,670)	(1,671)
Valuation difference on available-for-sale securities6,4817,388Deferred gains or losses on hedges(13)(6)Foreign currency translation adjustments2416Re-measurements of defined benefit plans(342)(331)Total accumulated other comprehensive income6,1497,067Total net assets52,72554,238	Total shareholders' equity	46,576	47,171
Deferred gains or losses on hedges(13)(6)Foreign currency translation adjustments2416Re-measurements of defined benefit plans(342)(331)Total accumulated other comprehensive income6,1497,067Total net assets52,72554,238	Accumulated other comprehensive income	_	
Foreign currency translation adjustments 24 16 Re-measurements of defined benefit plans (342) (331) Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Valuation difference on available-for-sale securities	6,481	7,388
Re-measurements of defined benefit plans(342)(331)Total accumulated other comprehensive income6,1497,067Total net assets52,72554,238	Deferred gains or losses on hedges	(13)	(6)
Total accumulated other comprehensive income 6,149 7,067 Total net assets 52,725 54,238	Foreign currency translation adjustments	24	16
Total net assets 52,725 54,238	Re-measurements of defined benefit plans	(342)	(331)
	Total accumulated other comprehensive income	6,149	7,067
Total net assets and liabilities 101,503 102,512	Total net assets	52,725	54,238
	Total net assets and liabilities	101,503	102,512

CONSOLIDATED STATEMENTS OF INCOME

	Three Months Ended		
	June 30, 2016	June 30, 2017	
Net sales	22,686	23,634	
Cost of sales	18,191	19,297	
Gross profit	4,495	4,337	
Selling, general, and administrative expenses	2,888	2,808	
Operating income	1,606	1,528	
Non-operating income			
Interest income	7	6	
Dividend income	178	197	
Foreign exchange gain	_	116	
Other	32	11	
Total non-operating income	219	331	
Non-operating expenses			
Interest expenses	18	39	
Foreign exchange loss	848	-	
Other	13_	6	
Total non-operating expenses	880	45	
Ordinary income	945	1,814	
Extraordinary income			
Gain on sales of investment securities		106	
Total extraordinary income		106	
Extraordinary loss			
Loss on retirement of noncurrent assets	161	163	
Total extraordinary loss	161	163	
Income before income taxes	784	1,757	
Income taxes - current	91	266	
Income taxes - deferred	179	264	
Total income taxes	271	531	
Net income	513	1,226	
Net income attributable to non-controlling interests	_		
Net income attributable to owners of parent	513	1.226	

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Three Months Ended		
	June 30, 2016	June 30, 2017	
Net income	513	1,226	
Other comprehensive income			
Valuation difference on available-for-sale securities	(704)	907	
Deferred gains or losses on hedges	2	7	
Foreign currency translation adjustments	(19)	(7)	
Re-measurements of defined benefit plans	14	11	
Total other comprehensive income	(706)	918	
Comprehensive income	(193)	2,144	
Comprehensive income attributable to:			
Owners of parent	(193)	2,144	
Non-controlling interests	_	_	

6. Notes to the Consolidated Financial Statements

(1) Notes regarding the going concern assumption: None

(2) Notes on significant changes in shareholders' equity: None

(3) Segment information

Three months ended June 30, 2016

(Millions of yen)

	Basic	Functional	Housing			Consolidated
	Chemical	Chemical	Facilities	Total	Adjustments*1	operating
	Products	Products	and Others			income *2
Net sales						
External sales	9,845	8,728	4,112	22,686	_	22,686
Intersegment sales	3	0	576	579	(579)	
or reclassifications	3	0	576	5/9	(579)	_
Total	9,849	8,728	4,688	23,265	(579)	22,686
Segment income	265	1,562	22	1,849	(242)	1,606

Notes 1: Adjustments of segment income of Y(242) million are corporate expenses not allocated to reportable segments. Corporate expenses are mainly expenses not attributable to a reporting segment and related to fundamental research and development as well as administrative departments.

Notes 2: Segment income has been adjusted for the operating income appearing in the quarterly consolidated statements of income.

Three months ended June 30, 2017

(Millions of yen)

	Basic	Functional	Housing			Consolidated
	Chemical	Chemical	Facilities	Total	Adjustments *1	operating
	Products	Products	and Others			income *2
Net sales						
External sales	10,018	9,683	3,932	23,634	_	23,634
Intersegment sales	1	,	202	205	(205)	
or reclassifications	I	ı	202	205	(205)	_
Total	10,019	9,684	4,135	23,839	(205)	23,634
Segment income	372	1,383	3	1,759	(230)	1,528

Notes 1: Adjustments of segment income of ¥(230) million are corporate expenses not allocated to reportable segments. Corporate expenses are mainly expenses not attributable to a reporting segment and related to fundamental research and development as well as administrative departments.

Notes 2: Segment income has been adjusted for the operating income appearing in the quarterly consolidated statements of income.